Glamorous Ai Ltd

Overview

Legal name

GLAMOROUS AI LTD

Region

North West England

Registered address

3RD FLOOR

1 ASHLEY ROAD

ALTRINCHAM

CHESHIRE

UNITED KINGDOM

WA14 2DT

Insolvency history

Latest accounts

Financial period: 1 Jan 2024 to 31 Dec 2024

FILLETEDACCOUNTS

Turnover

Unknown

Profit / Loss

Unknown

Employees

Company events

Reference milestones and recent Companies House filing stream events.

10 events

26 Mar

2027

Confirmation statement due

Confirmation Due

Next confirmation statement due date

30 Sep

2026

Accounts due

Accounts Due

Next accounts due date

12 Mar

2026

Confirmation statement filed

Confirmation

Last confirmation statement made up date

31 Dec

2024

Accounts filed

Accounts

Last accounts made up date

02 Oct

2024

Termination Director Company With Name Termination Date

Officers

TM01 | Transaction MzQzODEyNzk4N2FkaXF6a2N4

Published 02 Oct 2024 11:00

02 Oct

2024

Change Registered Office Address Company With Date Old Address New Address

Address

AD01 | Transaction MzQzODEyNzUzOWFkaXF6a2N4

Published 02 Oct 2024 10:56

27 Sep

2024

Accounts With Accounts Type Total Exemption Full

Accounts Analysed

AA | Transaction MzQzNzU0NTk5NGFkaXF6a2N4

Published 27 Sep 2024 02:51

13 Sep

2024

Notification Of A Person With Significant Control Statement

Persons-with-significant-control

PSC08 | Transaction MzQzNTYxNzI3MmFkaXF6a2N4

Published 13 Sep 2024 11:41

13 Sep

2024

Cessation Of A Person With Significant Control

Persons-with-significant-control

PSC07 | Transaction MzQzNTYxNjc1M2FkaXF6a2N4

Published 13 Sep 2024 11:36

13 Mar

2020

Incorporated

Inception

Company registered at Companies House

Public funding

1 award

First funded

2021

Funded years

2021

Age at first award

0 years

Projects

2021 Collaborative R&D Lead participant

Glioblastoma Multiforme Patient Stratification through Novel integration of Artificial Intelligence, Big Data and Phenotypic Screening

1 Mar 2021 to 31 Aug 2022

Awarded

£197,853

Total cost £282,647

Glamorous AI, a UK SME, is pioneering cutting-edge ML methods for drug and biomarker discovery. In collaboration with leading researchers from King's College London, the team aims to run a comprehensive study on GBM patients derived cell lines to deliver novel predictive biomarkers that enable efficient stratification strategies and reduce cost of treatment.

Product types

Collaborative R&D